IN8BIO, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
IN8BIO, INC. (INAB) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-12
- IN8BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- IN8BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- IN8BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- IN8BIO, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- IN8BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- IN8BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $714.00K.
- IN8BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- IN8BIO, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $3.05M, a 79.92% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $714.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $714.00K 10-Q · filed 2025-11-06 | $178.00K derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $714.00K 10-Q · filed 2025-08-07 | $178.00K derived: sum of 3 quarters · filed 2025-08-07 | $178.00K derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $714.00K 10-Q · filed 2025-05-07 | $178.00K derived: sum of 2 quarters · filed 2025-05-07 | $178.00K derived: sum of 3 quarters · filed 2025-05-07 | $714.00K derived: sum of 4 quarters · filed 2025-05-07 | |
| 2023-12-31 | -$536.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$536.00K derived: sum of 2 quarters · filed 2025-03-13 | $0.00 derived: sum of 3 quarters · filed 2025-03-13 | $0.00 10-K · filed 2025-03-13 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $536.00K derived: sum of 2 quarters · filed 2024-11-12 | $536.00K 10-Q · filed 2024-11-12 | $0.00 10-Q · filed 2023-11-09 | $536.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $536.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $536.00K 10-Q · filed 2024-08-08 | $536.00K derived: sum of 3 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $3.05M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $3.05M 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | -$1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$1.79M derived: sum of 2 quarters · filed 2023-03-30 | -$1.79M derived: sum of 3 quarters · filed 2023-03-30 | $1.69M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $3.48M 10-Q · filed 2022-11-10 | $3.48M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $3.48M 10-Q · filed 2022-08-12 | $3.48M derived: sum of 3 quarters · filed 2022-08-12 | $3.48M derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | $3.48M 10-Q · filed 2022-05-12 | $3.48M derived: sum of 2 quarters · filed 2022-05-12 | $3.48M derived: sum of 3 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |